PT3681500T - Utilização do cloridrato de pilocarpina para o tratamento da presbiopia - Google Patents

Utilização do cloridrato de pilocarpina para o tratamento da presbiopia

Info

Publication number
PT3681500T
PT3681500T PT197298839T PT19729883T PT3681500T PT 3681500 T PT3681500 T PT 3681500T PT 197298839 T PT197298839 T PT 197298839T PT 19729883 T PT19729883 T PT 19729883T PT 3681500 T PT3681500 T PT 3681500T
Authority
PT
Portugal
Prior art keywords
treatment
ocular conditions
pilocarpine hydrochloride
pilocarpine
hydrochloride
Prior art date
Application number
PT197298839T
Other languages
English (en)
Original Assignee
Allergan Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=66821312&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PT3681500(T) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Allergan Inc filed Critical Allergan Inc
Publication of PT3681500T publication Critical patent/PT3681500T/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/10—Ophthalmic agents for accommodation disorders, e.g. myopia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/186—Quaternary ammonium compounds, e.g. benzalkonium chloride or cetrimide
PT197298839T 2018-04-24 2019-04-24 Utilização do cloridrato de pilocarpina para o tratamento da presbiopia PT3681500T (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862662144P 2018-04-24 2018-04-24
US201862780117P 2018-12-14 2018-12-14
US201962790957P 2019-01-10 2019-01-10

Publications (1)

Publication Number Publication Date
PT3681500T true PT3681500T (pt) 2022-06-27

Family

ID=66821312

Family Applications (1)

Application Number Title Priority Date Filing Date
PT197298839T PT3681500T (pt) 2018-04-24 2019-04-24 Utilização do cloridrato de pilocarpina para o tratamento da presbiopia

Country Status (24)

Country Link
US (3) US10610518B2 (pt)
EP (2) EP3681500B1 (pt)
JP (2) JP6946575B2 (pt)
KR (2) KR20210005134A (pt)
CN (1) CN112272558A (pt)
AU (3) AU2019261598B9 (pt)
BR (1) BR112020021845A2 (pt)
CA (2) CA3074618C (pt)
CL (1) CL2020002734A1 (pt)
CO (1) CO2020014563A2 (pt)
DK (1) DK3681500T3 (pt)
ES (1) ES2920803T3 (pt)
HR (1) HRP20220762T1 (pt)
HU (1) HUE058931T2 (pt)
IL (1) IL278178A (pt)
LT (1) LT3681500T (pt)
MX (1) MX2020011301A (pt)
PH (1) PH12020551766A1 (pt)
PL (1) PL3681500T3 (pt)
PT (1) PT3681500T (pt)
RS (1) RS63360B1 (pt)
SG (1) SG11202010472XA (pt)
SI (1) SI3681500T1 (pt)
WO (1) WO2019209955A2 (pt)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019018749A1 (en) 2017-07-20 2019-01-24 Alan Laboratories, Inc. COMPOSITION AND METHODS FOR THE TREATMENT OF MYOPIA
WO2020087021A1 (en) 2018-10-26 2020-04-30 Ocuphire Pharma, Inc. Methods and compositions for treatment of presbyopia, mydriasis, and other ocular disorders
AU2021338618B2 (en) * 2020-09-11 2024-02-01 Intratus-Nevada, Inc. Compositions and methods for treating presbyopia, hyperopia, astigmatism, decreased stereopsis, and decreased contrast sensitivity
JP2024505517A (ja) * 2021-01-28 2024-02-06 グラウコス コーポレイション 製剤
WO2022232205A1 (en) * 2021-04-28 2022-11-03 Lenz Therapeutics, Inc. A method of reducing brow ache
CN115368310A (zh) 2021-05-18 2022-11-22 奥库菲尔医药公司 合成甲磺酸酚妥拉明的方法
CN116350790A (zh) * 2021-12-28 2023-06-30 沈阳兴齐眼药股份有限公司 组合物及其在制备用于治疗老花眼的药物中的用途
US20230263727A1 (en) * 2022-01-14 2023-08-24 Somerset Therapeutics, Llc Ophthalmologically suitable low pka buffer-containing pilocarpine compositions and related methods
US20230248699A1 (en) 2022-02-09 2023-08-10 Somerset Therapeutics, Llc Formulations of pilocarpine and brimonidine compounds and related methods
WO2023205695A1 (en) 2022-04-21 2023-10-26 Glaukos Corporation Ophthalmic topical cream compositions
WO2023225551A1 (en) 2022-05-18 2023-11-23 Glaukos Corporation Novel applications of zwitterions in ophthalmic topical cream compositions and preparations

Family Cites Families (74)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4474751A (en) 1983-05-16 1984-10-02 Merck & Co., Inc. Ophthalmic drug delivery system utilizing thermosetting gels
US4851521A (en) 1985-07-08 1989-07-25 Fidia, S.P.A. Esters of hyaluronic acid
IL92351A (en) 1988-11-29 1994-02-27 Allergan Inc Irvine Optimal aqueous solutions containing stabilized chlorine acid and inorganic salt
US5122522A (en) 1989-06-21 1992-06-16 The Trustees Of The University Of Pennsylvania Treatment and control of ocular development
US5055467A (en) 1989-11-13 1991-10-08 Allergan, Inc. Pharmaceutical epinephrine-pilocarpine compounds
US5496471A (en) 1990-01-08 1996-03-05 Ciba-Geigy Corporation Apparatus for removing components from solutions
US5776916A (en) 1990-07-10 1998-07-07 Gramer; Eugen Medicament for reducing the intraocular pressure
JP2536806B2 (ja) 1991-03-27 1996-09-25 アルコン ラボラトリーズ インコーポレイテッド ゲル化多糖類と微粉砕された薬剤担体とを組み合わせた局部眼科用組成物
US5459133A (en) 1992-06-05 1995-10-17 Telor Ophthalmic Pharmaceuticals, Inc. Methods and products for treating presbyopia
JPH07508751A (ja) 1992-07-02 1995-09-28 テラー・オフサルミック・ファーマシューティカルズ・インコーポレーテッド 老視治療のための方法および生産品
SE512871C2 (sv) 1992-08-20 2000-05-29 Santen Oy Oftalmologisk beredning innehållande pilokarpin och ytterligare medel för behandling av okular hypertension
WO1994010976A1 (en) * 1992-11-16 1994-05-26 Ciba Vision Ag, Hettlingen Polyvinyl alcohol/borate ophthalmic drug delivery system
US5422116A (en) 1994-02-18 1995-06-06 Ciba-Geigy Corporation Liquid ophthalmic sustained release delivery system
SE9401109D0 (sv) 1994-03-31 1994-03-31 Leiras Oy Opthalmic composition II
US5574518A (en) 1995-01-10 1996-11-12 Les Laboratoires Opti-Centre Inc. System incorporation two different sphero-non-spherical contact lenses for correcting presbytia
US5612027A (en) 1995-04-18 1997-03-18 Galin; Miles A. Controlled release of miotic and mydriatic drugs in the anterior chamber
US6291466B1 (en) 1998-07-30 2001-09-18 Allergan Sales, Inc. Cholinergic agents in the treatment of presbyopia
US6164282A (en) * 1999-01-27 2000-12-26 Allergan Sales, Inc. Methods for restoring and/or enhancing accommodation in pseudo phakia
CH693625A5 (it) 1999-02-18 2003-11-28 Inpharma Sa Composizioni farmaceutiche contenenti composti ad attività promotrice di assorbimento di principi attivi.
IT1306135B1 (it) * 1999-04-26 2001-05-30 Farmigea Spa Composizioni oftalmiche per il trattamento delle turbe visivecaratterizzate da ridotta sensibilita' al contrasto.
AU7581000A (en) 1999-09-16 2001-04-17 Gerald D. Horn A method for optimizing pupil size using alpha antagonist
US6420407B1 (en) 1999-09-16 2002-07-16 Gerald Horn Ophthalmic formulation which modulates dilation
TWI227143B (en) 1999-12-15 2005-02-01 Guo-Jiun Sung In situ gel formation for ophthalmic delivery by combining Pluronic/Carbopol medic composition and its preparing method
US6218428B1 (en) 2000-04-28 2001-04-17 Emil Chynn Ophthalmic composition
PE20020146A1 (es) 2000-07-13 2002-03-31 Upjohn Co Formulacion oftalmica que comprende un inhibidor de ciclooxigenasa-2 (cox-2)
EP1328214A4 (en) 2000-09-20 2009-07-29 Shahinian Lee Jr NASAL, INHALABLE AND LOCAL OPHTHALMIC PREPARATIONS AND MEDICATIONS WITH SPONTANEOUS CONSERVATION
US6273092B1 (en) 2000-09-22 2001-08-14 Gerard M. Nolan Methods for treating various eye disorders
ITMI20010708A1 (it) 2001-04-03 2002-10-03 Alessandro Randazzo Trattamento farmacologico degli aloni notturni e delle immagini fantasma con parasimpaticomimetici diluiti aceclidina/pilocarpina dopo inter
US20030139737A1 (en) 2002-01-24 2003-07-24 J.T. Lin Method and apparatus for treatment of presbyopia by lens relaxation and anterior shift
CA2866848C (en) 2002-07-30 2017-01-03 Omeros Corporation Ophthalmologic irrigation solutions and method
US20050261641A1 (en) 2002-09-26 2005-11-24 Warchol Mark P Method for ophthalmic administration of medicament
US20070211212A1 (en) 2002-09-26 2007-09-13 Percy Bennwik Eye state sensor
US20040078009A1 (en) 2002-10-17 2004-04-22 Lin J. T. Method and apparatus for the treatment of presbyopia and other eye disorders combining pharmocological and surgical means
US20050205101A1 (en) * 2002-10-17 2005-09-22 Lin J T Combined pharmocological and surgical method and system for the treatment of eye disorders
US20060177430A1 (en) 2002-12-20 2006-08-10 Chakshu Research Inc Treatment of ocular disorders with ophthalmic formulations containing methylsulfonylmethane as a transport enhancer
JP5583310B2 (ja) 2002-12-20 2014-09-03 チャクシュ・リサーチ・インコーポレーテッド 眼球の症状の予防及び治療のための眼科用製剤
CA2517145C (en) 2003-03-05 2017-08-01 Halozyme, Inc. Soluble hyaluronidase glycoprotein (shasegp), process for preparing the same, uses and pharmaceutical compositions comprising thereof
US20050119262A1 (en) 2003-08-21 2005-06-02 Pharmacia Corporation Method for preventing or treating an optic neuropathy with a cox-2 inhibitor and an intraocular pressure reducing agent
PL1754491T3 (pl) 2004-05-21 2010-08-31 Senju Pharma Co Preparat do oczu do wchłaniania przezskórnego zawierający agonistę receptora muskarynowego
US20050279369A1 (en) 2004-06-21 2005-12-22 Lin J T Method and apparatus for the treatment of presbyopia and glaucoma by ciliary body ablation
JP2008517671A (ja) 2004-10-22 2008-05-29 アキュフォーカス・インコーポレーテッド 光学装置を目の軸に位置合わせするためのシステム及び方法
WO2007027675A1 (en) 2005-09-02 2007-03-08 Theravida, Inc Therapy for the treatment of disease
US8158152B2 (en) 2005-11-18 2012-04-17 Scidose Llc Lyophilization process and products obtained thereby
PT2038252T (pt) 2006-07-12 2016-12-16 Univ Tennessee Res Found Acilanilidos substituidos e métodos de utilização dos mesmos
DE602006008643D1 (de) 2006-12-18 2009-10-01 Jorge Luis Benozzi Ophthalmische Zusammensetzungen von parasympathischen Stimulantia und Entzündungshemmer zur Verwendung bei der Behandlung von Presbyopie
EP2195033A1 (en) 2007-10-08 2010-06-16 Fovea Pharmaceuticals SA Aqueous ophthalmic formulations
AU2015202175A1 (en) 2007-12-15 2015-05-14 Anant Sharma Optical correction
GB0724558D0 (en) 2007-12-15 2008-01-30 Sharma Anant Optical correction
WO2010125416A1 (en) 2009-04-27 2010-11-04 Raouf Rekik Drug delivery to the anterior and posterior segments of the eye
US8299079B2 (en) 2009-05-22 2012-10-30 Kaufman Herbert E Preparations and methods for ameliorating or reducing presbyopia
WO2010135731A1 (en) 2009-05-22 2010-11-25 Kaufman Herbert E Preparations and methods for ameliorating or reducing presbyopia
TW201109325A (en) 2009-07-30 2011-03-16 Wakamoto Pharma Co Ltd Aqueous composition for eye drops
AR081049A1 (es) 2010-08-17 2012-06-06 Gonzalez Santos Alejandro Raul Medicamento oftalmico para el tratamiento de la hipermetropia
CN103415292A (zh) * 2011-01-26 2013-11-27 阿勒根公司 用于治疗眼科病症的雄性激素组合物
CA2849366C (en) 2011-09-20 2019-09-10 Juan Carlos Abad Compositions and methods for treating presbyopia, mild hyperopia, and irregular astigmatism
MY171920A (en) 2011-10-12 2019-11-07 Ascendis Pharma Ophthalmology Div A/S Prevention and treatment of ocular conditions
RU2014129268A (ru) 2011-12-16 2016-02-10 Аллерган, Инк. Офтальмологические составы, которые содержат привитые сополимеры поливинилкапролактам-поливинилацетат-полиэтиленгликоля
EP2630952A1 (en) 2012-02-23 2013-08-28 Novagali Pharma S.A. Self-preserved oil dispersions comprising boric acid
US10507245B2 (en) 2012-07-19 2019-12-17 Luis Felipe Vejarano Restrepo Ophthalmic formulation and method for ameliorating presbyopia
AU2014212275B2 (en) 2013-02-01 2018-09-06 Ocuphire Pharma, Inc. Methods and compositions for daily ophthalmic administration of phentolamine to improve visual performance
CA2899339C (en) 2013-02-01 2021-07-06 Ocularis Pharma, Llc Aqueous ophthalmic solutions of phentolamine and medical uses thereof
US9314427B2 (en) 2013-08-28 2016-04-19 Presbyopia Therapies Llc Compositions and methods for the improvement of distance vision and the treatment of refractive errors of the eye
US9968594B2 (en) 2013-08-28 2018-05-15 Presbyopia Therapies Llc Compositions and methods for the treatment of presbyopia
US9089562B2 (en) 2013-08-28 2015-07-28 Presbyopia Therapies Llc Compositions and methods for the treatment of presbyopia
US8859623B1 (en) 2013-11-14 2014-10-14 Paragon BioTeck, Inc. Methods and compositions of stable phenylephrine formulations
ES2538551B1 (es) 2013-12-20 2016-01-13 Eurocanarias Oftalmológica, Sl Composición Oftálmica para la corrección de la presbicia
JP5846338B2 (ja) * 2014-01-10 2016-01-20 参天製薬株式会社 ピリジルアミノ酢酸化合物を含む医薬製剤
US20170007637A1 (en) 2014-02-11 2017-01-12 Orasis Pharmaceuticals Ltd. Pharmacological ophthalmic composition for use in the correction of presbyopia and its administration
WO2016196367A1 (en) * 2015-05-29 2016-12-08 Sydnexis, Inc. D2o stabilized pharmaceutical formulations
US20190000808A1 (en) 2015-07-13 2019-01-03 Allergan, Inc. Composition and methods for the treatment of blephopharoptosis
CH711969A2 (it) 2015-12-29 2017-06-30 Pinelli Roberto Composizione per il trattamento della presbiopia.
US10231968B2 (en) 2016-08-01 2019-03-19 David R. Hardten Medicinal solution to be continuously or pulse-delivered to the eye for treating ophthalmological conditions/maladies
AU2017311636B2 (en) 2016-08-19 2023-08-10 Orasis Pharmaceuticals Ltd. Ophthalmic pharmaceutical compositions and uses relating thereto
EP4241759A1 (en) 2016-10-12 2023-09-13 PS Therapy, Inc. Artificial tear, contact lens and drug vehicle compositions and methods of use thereof

Also Published As

Publication number Publication date
CA3074618A1 (en) 2019-10-31
CN112272558A (zh) 2021-01-26
CL2020002734A1 (es) 2021-03-12
MX2020011301A (es) 2021-01-29
US20210008034A1 (en) 2021-01-14
DK3681500T3 (da) 2022-06-27
JP2022008403A (ja) 2022-01-13
JP7470667B2 (ja) 2024-04-18
US10610518B2 (en) 2020-04-07
AU2019261598B2 (en) 2020-05-14
EP3681500A2 (en) 2020-07-22
WO2019209955A2 (en) 2019-10-31
CA3074618C (en) 2022-08-02
HRP20220762T1 (hr) 2022-09-16
AU2020203311A1 (en) 2020-06-11
WO2019209955A3 (en) 2020-01-23
EP3681500B1 (en) 2022-03-23
AU2022201106A1 (en) 2022-03-10
EP4066830A1 (en) 2022-10-05
ES2920803T3 (es) 2022-08-09
KR20230079489A (ko) 2023-06-07
HUE058931T2 (hu) 2022-09-28
US20220241245A1 (en) 2022-08-04
AU2019261598A1 (en) 2020-03-19
AU2019261598B9 (en) 2020-05-28
LT3681500T (lt) 2022-06-27
PH12020551766A1 (en) 2021-07-12
KR20210005134A (ko) 2021-01-13
US11285134B2 (en) 2022-03-29
IL278178A (en) 2020-11-30
CA3162141A1 (en) 2019-10-31
RS63360B1 (sr) 2022-07-29
PL3681500T3 (pl) 2022-08-01
SG11202010472XA (en) 2020-11-27
SI3681500T1 (sl) 2022-09-30
CO2020014563A2 (es) 2021-02-26
US20190321337A1 (en) 2019-10-24
JP2021522256A (ja) 2021-08-30
JP6946575B2 (ja) 2021-10-06
BR112020021845A2 (pt) 2021-02-23

Similar Documents

Publication Publication Date Title
IL278178A (en) Use of pilocarpine hydrochloride to treat eye disorder
IL276398A (en) Combined treatment for mastocytosis
EP3823568A4 (en) GLAUCOMA SURGICAL TREATMENT
IL277333A (en) Methods for treating eye diseases
IL279260A (en) KDM1A inhibitors for the treatment of diseases
ZA202007055B (en) Compositions for the treatment of skin conditions
ZA202006610B (en) Compositions for the treatment of skin conditions
IL287280A (en) Compounds and methods for the treatment of ocular disorders
IL272601A (en) Pharmaceutical preparations for the treatment of ophthalmic conditions
IL284700A (en) Treatment of conditions of the eyes with similar-angiopoietin 7 inhibitors
IL287264A (en) Compounds and methods for the treatment of ocular disorders
IL291735A (en) Heteroarylbiphenylamines for the treatment of pd-l1 diseases
IL273531A (en) Ophthalmic preparations containing latanoprost for use in the treatment of eye diseases
GB2541840B (en) Ophthalmic composition for the treatment of ocular infection
IL284344A (en) Pharmaceutical preparations for the eyes and methods for the treatment of diseases of the surface of the eye
SG11202012473UA (en) Ophthalmic compositions and methods for the treatment of eye disorders
EP3643297A4 (en) OPHTHALMIC COMPOSITION FOR GLUCOMA TREATMENT
IL289436A (en) Methods for treating eye diseases
IL289371A (en) Methylthioninium for use in the treatment of synaptopathies
IL284629A (en) Methods for treating eye surface pain
GB201916506D0 (en) Corneal tissue
EP4069220A4 (en) OPHTHALMIC FORMULATIONS FOR THE TREATMENT OF PRESBYOPIA
GB2603379B (en) Avocatin B for the treatment of diseases and conditions
SG11202009006WA (en) Polysaccharides for the treatment of ocular conditions
GB201901130D0 (en) Formulation for the treatment of tendinopathies